ClinicalTrials.gg
CompletedNCT00321620Updated Aug 29, 2018Results posted

Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer

A Phase 3 interventional study of zoledronic acid and denosumab in Bone Metastases, sponsored by Amgen. Completed. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-29.

Sponsored by Amgen · Phase 3, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,904
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Study summary

The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid (Zometa®) in the treatment of bone metastases in men with hormone-refractory prostate cancer

02

Conditions studied

  • Bone Metastases

Browse trials for

Keywords

  • Bone metastases
  • Hormone-refractory prostate cancer
  • Skeletal
  • Fractures
  • Compressions
  • Bisphosphonates
03

In context

Fractures, Bone

725 studies on the registry are indexed under Fractures, Bone; 116 are open to participants now.

This study's enrollment of 1,904 is above the median of 80 across 458 interventional studies indexed under Fractures, Bone.

Browse Fractures, Bone studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men >/= 18 years of age with confirmed prostate cancer
  • Radiographic evidence of at least one bone
  • Failure of at least one hormonal therapy as evidenced by a rising PSA
  • Serum testosterone level of \<50 ng/dL
  • PS 0, 1, or 2
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Current or prior IV bisphosphonate administration
  • Current or prior oral bisphosphonates for bone mets
  • of less than 6 months
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,904 participants (actual)

Study arms

  • Active comparator
    zoledronic acid

    Drug: zoledronic acid

  • Experimental
    denosumab

    Biological: denosumab

Interventions

  • Q4W 4 mg zoledronic acid IV over minimum 15 minutes and 120 mg denosumab placebo SC

    Also known as: Zometa

  • Biologicaldenosumab

    Q4W 120 mg denosumab SC and 4 mg zoledronic acid placebo IV over a minimum of 15 minutes

06

What researchers measure

Primary outcomes

  1. Time to the First On-Study SRE (Non-inferiority)

    Time to the first on-study skeletal-related event (SRE) analyzed for non-inferiority. Kaplan-Meier estimates of the median and its dispersion are reported.

    Time frame: Up to 40.5 months

Secondary outcomes

  1. Time to the First On-Study SRE (Superiority)

    Time to the first on-study skeletal-related event (SRE), analyzed for superiority of denosumab. Kaplan-Meier estimates of the median and its dispersion are reported.

    Time frame: Up to 40.5 months

  2. Time to the First-And-Subsequent On-Study SRE

    Time to the first-and-subsequent on-study skeletal-related event (SRE), analyzed for superiority of denosumab using multiple event analysis, the event must occur at least 21 days after the previous SRE. This outcome measure utilizes multiple event times, was analyzed based on a proportional mean model, and is therefore more appropriately summarized by the cumulative mean number of events.

    Time frame: Up to 40.5 months

07

Results

Posted Mar 21, 2014

Participant flow

Participants were enrolled from 12 May 2006 through 18 December 2008.

Participant flow — Overall Study
MilestoneZoledronic AcidDenosumab
Started951950
Received investigational product946942
Completed208228
Not completed743722
Withdrew: Death269294
Withdrew: Withdrawal by subject164147
Withdrew: Disease progression113117
Withdrew: Adverse event4356
Withdrew: Lost to follow-up139
Withdrew: Physician decision41
Withdrew: Noncompliance147
Withdrew: Protocol deviation43
Withdrew: Ineligibility determined23
Withdrew: Participant request7552
Withdrew: Other4233

Outcome measures

PrimaryTime to the First On-Study SRE (Non-inferiority)

Time to the first on-study skeletal-related event (SRE) analyzed for non-inferiority. Kaplan-Meier estimates of the median and its dispersion are reported.

Time frame:
Up to 40.5 months
Reported as:
Median · Days
Time to the First On-Study SRE (Non-inferiority)
DaysZoledronic AcidDenosumab
Time to the First On-Study SRE (Non-inferiority)521.0 (456.00 to 592.00)629.0 (573.00 to 757.00)
Statistical analysis
  • Zoledronic Acid vs Denosumab · Regression, Cox · p = 0.0002 · Hazard ratio (hr): 0.82 · 95% CI 0.71 to 0.95Stratified by the randomization stratification factors (previous skeletal-related event, prostate-specific antigen level, and current chemotherapy)
SecondaryTime to the First On-Study SRE (Superiority)

Time to the first on-study skeletal-related event (SRE), analyzed for superiority of denosumab. Kaplan-Meier estimates of the median and its dispersion are reported.

Time frame:
Up to 40.5 months
Reported as:
Median · Days
Time to the First On-Study SRE (Superiority)
DaysZoledronic AcidDenosumab
Time to the First On-Study SRE (Superiority)521.0 (456.0 to 592.0)629.0 (573.00 to 757.00)
Statistical analysis
  • Zoledronic Acid vs Denosumab · Regression, Cox · p = 0.0085 · Hazard ratio (hr): 0.82 · 95% CI 0.71 to 0.95Stratified by the randomization stratification factors (previous skeletal-related event, prostate-specific antigen level, and current chemotherapy).
SecondaryTime to the First-And-Subsequent On-Study SRE

Time to the first-and-subsequent on-study skeletal-related event (SRE), analyzed for superiority of denosumab using multiple event analysis, the event must occur at least 21 days after the previous SRE. This outcome measure utilizes multiple event times, was analyzed based on a proportional mean model, and is therefore more appropriately summarized by the cumulative mean number of events.

Time frame:
Up to 40.5 months
Reported as:
Number · Events
Time to the First-And-Subsequent On-Study SRE
EventsZoledronic AcidDenosumab
Time to the First-And-Subsequent On-Study SRE584494
Statistical analysis
  • Zoledronic Acid vs Denosumab · Anderson-Gill model · p = 0.0085 · Rate ratio: 0.82 · 95% CI 0.71 to 0.94Stratified by the randomization stratification factors (previous skeletal-related event, prostate-specific antigen level, and current chemotherapy).

Adverse events

Collected over up to 3 years 5 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zoledronic Acid 4 mg Q4W—568/945 (60.1%)853/945 (90.3%)
Denosumab 120 mg Q4W—594/943 (63%)844/943 (89.5%)
Most frequent serious events
Showing 10 of 561
Most frequent serious events
EventZoledronic Acid 4 mg Q4WDenosumab 120 mg Q4W
AnaemiaBlood and lymphatic system disorders82/945108/943
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)56/94534/943
PneumoniaInfections and infestations24/94540/943
AstheniaGeneral disorders29/94537/943
HaematuriaRenal and urinary disorders37/94523/943
DehydrationMetabolism and nutrition disorders19/94536/943
DyspnoeaRespiratory, thoracic and mediastinal disorders28/94536/943
Back painMusculoskeletal and connective tissue disorders36/94529/943
Urinary retentionRenal and urinary disorders35/94532/943
Bone painMusculoskeletal and connective tissue disorders34/94524/943
Most frequent other events
Showing 10 of 38
Most frequent other events
EventZoledronic Acid 4 mg Q4WDenosumab 120 mg Q4W
AnaemiaBlood and lymphatic system disorders313/945300/943
Back painMusculoskeletal and connective tissue disorders271/945290/943
NauseaGastrointestinal disorders242/945271/943
Decreased appetiteMetabolism and nutrition disorders263/945264/943
FatigueGeneral disorders217/945247/943
ConstipationGastrointestinal disorders247/945233/943
Bone painMusculoskeletal and connective tissue disorders230/945221/943
AstheniaGeneral disorders226/945219/943
ArthralgiaMusculoskeletal and connective tissue disorders197/945188/943
Pain in extremityMusculoskeletal and connective tissue disorders184/945192/943

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Zoledronic AcidDenosumabTotal
Mean71.0 ± 8.470.5 ± 8.770.8 ± 8.6
Sex: Female, Male
Sex: Female, Male(Participants)Zoledronic AcidDenosumabTotal
Female000
Male9519501901
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Zoledronic AcidDenosumabTotal
White or Caucasian8108291639
Black or African American353873
Hispanic or Latino5745102
Asian262248
Native Hawaiian or Other Pacific Islander112
Other221537
Prostate-Specific Antigen (PSA) Stratification Factor
Prostate-Specific Antigen (PSA) Stratification Factor(Participants)Zoledronic AcidDenosumabTotal
PSA level < 10 ng/mL145145290
PSA level ≥ 10 ng/mL8068051611
Previous Skeletal-Related Event (SRE) Stratification Factor
Previous Skeletal-Related Event (SRE) Stratification Factor(Participants)Zoledronic AcidDenosumabTotal
Yes231232463
No7207181438
Current Prostate Cancer Chemotherapy Stratification Factor
Current Prostate Cancer Chemotherapy Stratification Factor(Participants)Zoledronic AcidDenosumabTotal
Yes132132264
No8198181637
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011 Mar 5;377(9768):813-22. doi: 10.1016/S0140-6736(10)62344-6. Epub 2011 Feb 25. PubMed 21353695 ↗
  • Smith MR, Coleman RE, Klotz L, Pittman K, Milecki P, Ng S, Chi KN, Balakumaran A, Wei R, Wang H, Braun A, Fizazi K. Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events. Ann Oncol. 2015 Feb;26(2):368-74. doi: 10.1093/annonc/mdu519. Epub 2014 Nov 25. Erratum In: Ann Oncol. 2015 Jun;26(6):1274. doi: 10.1093/annonc/mdv155. PubMed 25425475 ↗
  • Fizazi K, Massard C, Smith M, Rader M, Brown J, Milecki P, Shore N, Oudard S, Karsh L, Carducci M, Damiao R, Wang H, Ying W, Goessl C. Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer. Eur Urol. 2015 Jul;68(1):42-50. doi: 10.1016/j.eururo.2014.10.001. Epub 2014 Oct 29. PubMed 25449207 ↗
  • Jakob T, Tesfamariam YM, Macherey S, Kuhr K, Adams A, Monsef I, Heidenreich A, Skoetz N. Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. Cochrane Database Syst Rev. 2020 Dec 3;12(12):CD013020. doi: 10.1002/14651858.CD013020.pub2. PubMed 33270906 ↗
  • Stopeck AT, Fizazi K, Body JJ, Brown JE, Carducci M, Diel I, Fujiwara Y, Martin M, Paterson A, Tonkin K, Shore N, Sieber P, Kueppers F, Karsh L, Yardley D, Wang H, Maniar T, Arellano J, Braun A. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer. 2016 Jan;24(1):447-455. doi: 10.1007/s00520-015-2904-5. Epub 2015 Sep 3. Erratum In: Support Care Cancer. 2016 Jan;24(1):457-458. doi: 10.1007/s00520-015-2985-1. PubMed 26335402 ↗
  • Body JJ, Bone HG, de Boer RH, Stopeck A, Van Poznak C, Damiao R, Fizazi K, Henry DH, Ibrahim T, Lipton A, Saad F, Shore N, Takano T, Shaywitz AJ, Wang H, Bracco OL, Braun A, Kostenuik PJ. Hypocalcaemia in patients with metastatic bone disease treated with denosumab. Eur J Cancer. 2015 Sep;51(13):1812-21. doi: 10.1016/j.ejca.2015.05.016. Epub 2015 Jun 17. PubMed 26093811 ↗
  • de Liano AG, Reig O, Mellado B, Martin C, Rull EU, Maroto JP. Prognostic and predictive value of plasma testosterone levels in patients receiving first-line chemotherapy for metastatic castrate-resistant prostate cancer. Br J Cancer. 2014 Apr 29;110(9):2201-8. doi: 10.1038/bjc.2014.189. Epub 2014 Apr 10. PubMed 24722180 ↗
  • von Moos R, Body JJ, Egerdie B, Stopeck A, Brown JE, Damyanov D, Fallowfield LJ, Marx G, Cleeland CS, Patrick DL, Palazzo FG, Qian Y, Braun A, Chung K. Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Support Care Cancer. 2013 Dec;21(12):3497-507. doi: 10.1007/s00520-013-1932-2. Epub 2013 Aug 22. PubMed 23975226 ↗
  • Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012 Nov;48(16):3082-92. doi: 10.1016/j.ejca.2012.08.002. Epub 2012 Sep 10. PubMed 22975218 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2006 to primary completion in Oct 2009, 42 months.

Results were first posted in Mar 2014, 4 years 5 months after primary completion. A results delay was requested in Jun 2010.

Of 14 phase 3 interventional studies under Fractures, Bone, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 46. This study's 42 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2006
First posted
May 4, 2006
StartActual
Apr 1, 2006
Primary completionActual
Oct 1, 2009
CompletionActual
Feb 24, 2012
Results delay requested
Jun 29, 2010
Results first posted
Mar 21, 2014
Last update
Aug 29, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00321620
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
May 4, 2006
Start date
Apr 1, 2006
Primary completion
Oct 1, 2009
Completion
Feb 24, 2012
Results posted
Mar 21, 2014
Last update
Aug 29, 2018

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion